Clinical study on high-dose ilaprazole combined with amoxicillin for newly diagnosed elderly patients with <italic style="font-style: italic">Helicobacter pylori </italic>infection

LI Chen; WANG Yujing; MAO Jianna; GUO Hao; SHEN Yuhou; DONG Zhichao; YAN Binbin

doi:10.6039/j.issn.1001-0408.2025.14.18

您当前的位置：

首页 >

文章列表页 >

Clinical study on high-dose ilaprazole combined with amoxicillin for newly diagnosed elderly patients with Helicobacter pylori infection

更新时间：2025-09-24

- Clinical study on high-dose ilaprazole combined with amoxicillin for newly diagnosed elderly patients with Helicobacter pylori infection
- ZHONGGUO YAOFANG Vol. 36, Issue 14, Pages: 1792-1796(2025)
- 作者机构：
  
  1.新乡市中心医院消化内科，河南新乡　453001
  2.新乡市中心医院肿瘤外科，河南新乡　453001
  3.河南省人民医院消化内科，郑州　450003
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2025.14.18
  CLC： R975
- Received：14 March 2025，
  
  Revised：2025-06-24，
  
  Accepted：24 June 2025，
  
  Published：30 July 2025
- 稿件说明：
移动端阅览
李辰,王玉静,毛建娜,等.高剂量艾普拉唑联合阿莫西林用于老年新发幽门螺杆菌感染患者的临床研究[J].中国药房,2025,36(14):1792-1796.

LI Chen,WANG Yujing,MAO Jianna,et al.Clinical study on high-dose ilaprazole combined with amoxicillin for newly diagnosed elderly patients with Helicobacter pylori infection[J].ZHONGGUO YAOFANG,2025,36(14):1792-1796.
李辰,王玉静,毛建娜,等.高剂量艾普拉唑联合阿莫西林用于老年新发幽门螺杆菌感染患者的临床研究[J].中国药房,2025,36(14):1792-1796. DOI： 10.6039/j.issn.1001-0408.2025.14.18.

LI Chen,WANG Yujing,MAO Jianna,et al.Clinical study on high-dose ilaprazole combined with amoxicillin for newly diagnosed elderly patients with Helicobacter pylori infection[J].ZHONGGUO YAOFANG,2025,36(14):1792-1796. DOI： 10.6039/j.issn.1001-0408.2025.14.18.

摘要

目的

评价高剂量艾普拉唑联合阿莫西林用于老年新发幽门螺杆菌（Hp）感染患者的疗效及安全性，分析Hp感染根除治疗失败的独立危险因素。

方法

选取2021年8月1日至2024年12月1日就诊于新乡市中心医院的200例老年新发Hp感染患者，按随机数字表法分为对照组和研究组，每组各100例。对照组患者给予经典四联方案（阿莫西林胶囊+克拉霉素片+枸橼酸铋钾片+艾普拉唑肠溶片），研究组患者给予高剂量艾普拉唑肠溶片+阿莫西林胶囊，所有患者均用药2周。比较意向性治疗（ITT）、方案治疗（PP）分析集中两组患者的Hp根除率，记录两组患者的不良反应发生情况；采用多因素Logistic回归分析筛选影响Hp感染根除治疗失败的独立危险因素。

结果

ITT及PP分析集中，两组患者的Hp根除率比较，差异均无统计学意义（

＞0.05）。两组患者的轻、中度不良反应发生率比较，差异均无统计学意义（

＞0.05）。体重指数（BMI）≤18.5 kg/m

、BMI＞23.9 kg/m

、农村居住、合并糖尿病及合并心脏病经分析确定为影响Hp感染根除治疗失败的独立危险因素（

＜0.05）。

结论

高剂量艾普拉唑联合阿莫西林用于老年新发Hp感染患者的疗效和安全性均与经典四联方案相当。BMI≤18.5 kg/m

、BMI＞23.9 kg/m

、农村居住、合并糖尿病及合并心脏病是Hp感染根除治疗失败的独立危险因素。

Abstract

OBJECTIVE

To evaluate the efficacy and safety of high-dose ilaprazole combined with amoxicillin for newly diagnosed elderly patients with

Helicobacter pylori

（Hp） infection， and analyze independent risk factors for failure of Hp infection eradication treatment.

METHODS

Totally 200 cases of newly diagnosed elderly patients with Hp infection in Xinxiang Central Hospital from August 1， 2021 to December 1， 2024 were selected and randomly divided into control group and study group， with 100 cases in each group. The control group was treated with classic quadruple therapy regimen （Amoxicillin capsules+ Clarithromycin tablets+Bismuth potassium citrate tablets+Ilaprazole enteric-coated tablets）. The study group was treated with high-dose Ilaprazole enteric-coated tablets+Amoxicillin capsules. All patients were administered medication for 2 weeks. Hp eradication rates in the two groups were compared using intention-to-treat （ITT） and per-protocol （PP） analyses. The incidence of adverse reactions in both groups was also recorded. The multiple-factor Logistic regression analysis was used to identify independent risk factors for failure of Hp infection eradication treatment.

RESULTS

In ITT and PP analyses， there was no significant difference of Hp eradication rates between the two groups （

＞0.05）. There was no significant difference in incidence of mild to moderate adverse reactions between the two groups （

＞0.05）. BMI ≤18.5 kg/m

， BMI ＞23.9 kg/m

， rural residence， concomitant diabetes and concomitant heart disease were identified as independent risk factors influencing the failure of Hp infection eradication treatment （

＜0.05）.

CONCLUSIONS

The efficacy and safety of high-dose ilaprazole combined with amoxicillin are comparable to classic quadruple therapy regimen in treating newly diagnosed elderly patients with Hp infection. Independent risk factors influencing the failure of Hp infection eradication treatment include BMI ≤18.5 kg/m

， BMI ＞23.9 kg/m

， rural residence， concomitant diabetes and concomitant heart disease.

关键词

Keywords

references

王伯英，张丽娜，苗雨，等 . 基于胃镜筛查胃癌及癌前病变危险因素 [J ] . 宁夏医科大学学报， 2023 ， 45 （ 10 ）： 1021 - 1027 .

陆伦根，沈波 . 消化系统疾病2021年度进展述评 [J ] . 西南医科大学学报， 2022 ， 45 （ 1 ）： 1 - 6 .

JONAITIS P ， KUPCINSKAS J ， GISBERT J P ， et al . Helicobacter pylori eradication treatment in older patients [J ] . Drugs Aging ， 2024 ， 41 （ 2 ）： 141 - 151 .

SHI R ， YU S Y ， LARBI A ， et al . Specific and cumulative infection burden and mild cognitive impairment and dementia：a population-based study [J ] . Brain Behav Immun ， 2024 ， 121 ： 155 - 164 .

中华医学会消化病学分会，中华医学会消化病学分会消化系统肿瘤协作组 . 中国慢性胃炎诊治指南（2022年，上海） . [J ] . 中华消化杂志， 2023 ， 43 （ 3 ）： 145 - 175 .

FENG J H ， CHENG J ， LAO Y J ， et al . The efficacy and safety of vonoprazan-amoxicillin dual therapy in eradi-cating Helicobacter pylori ：a systematic review and meta-analysis [J ] . Eur J Med Res ， 2023 ， 28 （ 1 ）： 272 .

CHEN F C ， HE X D ， FANG B X ， et al . Simultaneous quantitative analysis of six proton-pump inhibitors with a single marker and evaluation of stability of investigated drugs in polypropylene syringes for continuous infusion use [J ] . Drug Des Devel Ther ， 2020 ， 14 ： 5689 - 5698 .

ZHANG X D ， ZHANG D Y ， CHEN R X ， et al . Ilaprazole-amoxicillin dual therapy at high dose as a first-line treatment for Helicobacter pylori infection in Hainan：a single-center，open-label，noninferiority，randomized controlled trial [J ] . BMC Gastroenterol ， 2023 ， 23 （ 1 ）： 249 .

中华医学会消化病学分会幽门螺杆菌学组 . 2022中国幽门螺杆菌感染治疗指南 [J ] . 胃肠病学， 2022 ， 27 （ 3 ）： 150 - 162 .

杨延音，董志，夏永鹏 . 新《药品不良反应报告和监测管理办法》重点解读及应对模式探讨 [J ] . 中国药学杂志， 2012 ， 47 （ 15 ）： 1263 - 1264 .

QIAN H S ， LI W J ， DANG Y N ， et al . Ten-day vonoprazan-amoxicillin dual therapy as a first-line treatment of Helicobacter pylori infection compared with bismuth-containing quadruple therapy [J ] . Am J Gastroenterol ， 2023 ， 118 （ 4 ）： 627 - 634 .

BUJANDA L ， NYSSEN O P ， RAMOS J ， et al . Effectiveness of Helicobacter pylori treatments according to anti-biotic resistance [J ] . Am J Gastroenterol ， 2024 ， 119 （ 4 ）： 646 - 654 .

YANG J ， ZHANG Y ， FAN L ， et al . Eradication efficacy of modified dual therapy compared with bismuth-containing quadruple therapy as a first-line treatment of Helicobacter pylori [J ] . Am J Gastroenterol ， 2019 ， 114 （ 3 ）： 437 - 445 .

SONG Z Q ， ZHOU L Y ， XUE Y ， et al . A comparative study of 14-day dual therapy（esomeprazole and amoxicillin four times daily）and triple plus bismuth therapy for first-line Helicobacter pylori infection eradication：a randomized trial [J ] . Helicobacter ， 2020 ， 25 （ 6 ）： e12762 .

TAI W C ， LIANG C M ， KUO C M ， et al . A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti- Helicobacter pylori treatment in Taiwan：a prospective randomized trial [J ] . J Antimicrob Chemother ， 2019 ， 74 （ 6 ）： 1718 - 1724 .

GAO N ， YAN S ， CHEN B X . Effects of lansoprazole and omeprazole combined with antimicrobial agents on gastric juice pH and inflammatory factors in elderly patients with Hp positive gastric ulcer [J ] . Altern Ther Health Med ， 2023 ， 29 （ 2 ）： 213 - 217 .

BI H X ， CHEN X X ， CHEN Y X ， et al . Efficacy and safety of high-dose esomeprazole-amoxicillin dual therapy for Helicobacter pylori rescue treatment：a multicenter，prospective，randomized，controlled trial [J ] . Chin Med J（Engl）， 2022 ， 135 （ 14 ）： 1707 - 1715 .

YUN J W ， WU Z P ， QI G Q ， et al . The high-dose amoxicillin-proton pump inhibitor dual therapy in eradication of Helicobacter pylori infection [J ] . Expert Rev Gastroenterol Hepatol ， 2021 ， 15 （ 2 ）： 149 - 157 .

WANG H ， KONG Q Z ， LI Y Y ， et al . High-dose dual therapy versus bismuth-containing quadruple therapy for the eradication of Helicobacter pylori ：a systematic review and meta-analysis [J ] . J Dig Dis ， 2024 ， 25 （ 3 ）： 163 - 175 .

AIMASSO U ， D’ONOFRIO V ， D’EUSEBIO C ， et al . Helicobacter pylori and nutrition：a bidirectional communication [J ] . Minerva Gastroenterol Dietol ， 2019 ， 65 （ 2 ）： 116 - 129 .

XIAO T ， LIU K ， GAO Q W ， et al . Design，synthesis，and evaluation of carbonate-linked halogenated phenazine-quinone prodrugs with improved water-solubility and potent antibacterial profiles [J ] . ACS Infect Dis ， 2023 ， 9 （ 4 ）： 899 - 915 .

AUMPAN N ， ISSARIYAKULKARN N ， MAHACHAI V ， et al . Management of Helicobacter pylori treatment fai-lures：a large population-based study（HP treatment failures trial） [J ] . PLoS One ， 2023 ， 18 （ 11 ）： e0294403 .

LUZKO I ， NYSSEN O P ， MOREIRA L ， et al . Safety profile of Helicobacter pylori eradication treatments：literature review and updated data of the European Registry on Helicobacter pylori management（Hp-EuReg） [J ] . Expert Opin Drug Saf ， 2024 ， 23 （ 5 ）： 553 - 564 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Study on the effect and safety of ciprofol combined with local anesthesia on elderly patients undergoing hemorrhoidectomy

Study on population pharmacokinetics of dabigatran in elderly patients with non-valvular atrial fibrillation

临床药师参与肺栓塞合并心功能不全老年患者治疗的药学实践

我院门诊老年原发性高血压患者用药情况的调查分析

某三级甲等医院2011年8月至2012年8月门诊老年患者维生素应用分析

Related Author

LI Fujun

ZOU Helin

FENG Jiahui

ZHU Zhu

TAO Hong

SHEN Zhu

YANG Yezhou

QU Yuchen

Related Institution

Ruikang Clinical Medical College， Guangxi University of Chinese Medicine

Dept. of Anesthesiology， Mianyang Chinese Medicine Hospital

Dept. of Anesthesiology， Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine

Dept. of Pharmacy， the Second Affiliated Hospital of Soochow University

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰

Clinical study on high-dose ilaprazole combined with amoxicillin for newly diagnosed elderly patients with Helicobacter pylori infection

DOI：10.6039/j.issn.1001-0408.2025.14.18

摘要

Abstract

关键词

Keywords

references